Analyst Price Target is $18.00
▲ +594.98% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lumos Pharma in the last 3 months. The average price target is $18.00, with a high forecast of $28.00 and a low forecast of $10.00. The average price target represents a 594.98% upside from the last price of $2.59.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Lumos Pharma. This Buy consensus rating has held steady for over two years.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Read More